Content area

|
|

Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling

Forfatter(e)

Mette Vadstrup1, Tobias Bomholt1, Kirsten Nørgaard2, Ajenthen G. Ranjan2, Marianne Rix1, Thomas Almdal3, Therese Adrian1, Bo Feldt-Rasmussen1 & Mads Hornum1

1) Nefrologisk Afdeling, Rigshospitalet, 2) Steno Diabetes Center, Copenhagen, 3) Medicinsk Endokrinologisk Klinik, Rigshospitalet

Ugeskr Læger 2020;181:V03200166

Reference: 
UgeskrLæger 2020;182:V03200166
Continuous glucose monitoring of patients with type 1- and type 2 diabetes on haemodialysis

Mette Vadstrup, Tobias Bomholt, Kirsten Nørgaard, Ajenthen G. Ranjan, Marianne Rix, Thomas Almdal, Therese Adrian, Bo Feldt-Rasmussen & Mads Hornum

Ugeskr Læger 2019;181:V03200166

Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Knud Raben-Pedersen | 21/09
6 kommentarer
af Peter Matzen | 21/09
1 Kommentar
af Finn Vallø Hansen | 21/09
1 Kommentar
af Johan Ludvig Reventlow | 19/09
2 kommentarer
af Andreas Gothardt Lundh | 17/09
1 Kommentar
af Bjørn Søeberg | 17/09
33 kommentarer
af Lene Annette Norberg | 15/09
5 kommentarer
af Søren Holm | 14/09
1 Kommentar